MOLN Molecular Partners AG

Biotech Analyst Ratings

Latest News

1. 12 May 2022 Interim Management Statement Q1 2022 of Molecular Partners: Cash Runway into 2026 and Portfolio Progress Highlight Strategic Momentum

   ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2022 (GLOBE NEWSWIRE) --  Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its interim management statement for the quarter ending March 31, 2022.

   "Following a significant capital inflow in January, resulting from Novartis exercising its right to in-license global rights to ensovibep, we are leveraging our strong cash position to follow our strategy; to prioritize candidates where DARPins have an innate advantage over other approaches. Programs like ensovibep, the breakthrough design of MP0533 and our new research…

   View Full Article
2. 11 May 2022 Molecular Partners to Participate in Upcoming Healthcare Investor Conferences

   ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its management team will participate in two upcoming investor events. In addition, the Company will publish its Q1 2022 earnings report on May 12, after the close of trading at the NASDAQ exchange.
   

   Conference Details:

   • 2022 RBC Capital Markets Global Healthcare Conference, in-person, May 17-18, 2022
     
     
     • Fireside chat – Tuesday, May 17, 2022, at 9:00am ET
       
       
   • BioEquity Europe 2022 – virtual 1x1 meetings, Monday-Tuesday, May 23-24, 2022

   • Virtual presentation…

   View Full Article
3. 03 May 2022 Molecular Partners CEO, Patrick Amstutz, Elected President of the Swiss Biotech Association

   BASEL, Switzerland and ZURICH-SCHLIEREN, Switzerland, May 03, 2022 (GLOBE NEWSWIRE) -- The Swiss Biotech Association and Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Molecular Partners' Chief Executive Officer Patrick Amstutz, Ph.D., has been elected President of the Swiss Biotech Association Board of Directors.

   "Switzerland is one of the leading global hubs for the life sciences industry and the birthplace of some of the world's most transformative medicines. It is a great privilege to lead the Swiss Biotech Association at a time of unprecedented global medical need and of therapeutic innovation," said…

   View Full Article
4. 26 April 2022 Molecular Partners to Regain Global Rights for MP0310 from Amgen

   ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: 
   Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Amgen, its collaboration partner for MP0310 (AMG 506), has informed the Company of their decision to return global rights of MP0310 to Molecular Partners following a strategic pipeline review. Molecular Partners is presently conducting a phase 1 study of MP0310 and will look to present full phase 1 data at a scientific conference when available.

   "We would like to thank Amgen for a very fruitful collaboration which has led us to the…

   View Full Article
5. 26 April 2022 Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings Call

   ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, is providing an update following comments provided by Novartis during its quarterly earnings call today. In the call, Novartis' CEO, Vas Narasimhan stated that Emergency Use Application (EUA) for ensovibep, which is filed and in review with the U.S. Food and Drug Administration (FDA), may require additional clinical data to be authorized.
   

   Vas Narasimhan also noted the current omicron wave of SARS-Cov-2, and the lower incidents of hospitalization associated…

   View Full Article